BIOGEN INC. is 21.9x more valuable than Maze Therapeutics, Inc. by market capitalization ($28.73 B vs $1.31 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MAZE | BIIB |
|---|---|---|
| Market cap | $1.31 B | $28.73 B |
| US-listed rank | #2433 | #480 |
| Revenue (latest FY) | $167.50M | $9.89B |
| Net income (latest FY) | -$131.12M | $1.29B |
| Net margin | -78.3% | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 165 | 2,690 |
BIOGEN INC. is 21.9x more valuable than Maze Therapeutics, Inc. by market capitalization ($28.73 B vs $1.31 B).
In their latest fiscal years, Maze Therapeutics, Inc. reported $167.50M in revenue while BIOGEN INC. reported $9.89B.
Full pages: Maze Therapeutics, Inc. and BIOGEN INC., or browse the full rankings.